Climate change the most material ESG issue: Poll
The importance of environmental, social, and governance (ESG) factors for sustainability in investment and business decisions have been accentuated by the COVID-19 pandemic.
Investment
Science park merger creates UK’s largest life sciences ecosystem
Three companies have merged to form the UK’s first nationwide life sciences ecosystem, boosting R&D...
AZ’s proposed acquisition of rare disease-focused Alexion gets US clearance
AstraZeneca’s proposed $39bn acquisition of rare disease therapy company Alexion Pharmaceuticals has passed a US Federal Trade Commission review.
Boehringer Ingelheim reports positive business growth in 2020
Boehringer Ingelheim has seen positive business momentum in 2020, according to an annual report published by the biopharmaceutical company on...
Public benefit: could the PBC model help pharma balance profits and patients?
Pharma’s public reputation is far from positive. Could switching from being a traditional for-profit corporation to a public benefit corporation...
SIRION and Sanofi partner on next-gen AAV gene therapy vectors
Germany-based SIRION Biotech has signed a gene therapy collaboration with French pharma giant Sanofi. The pair will work with Heidelberg University Hospital’s Professor Dirk Grimm in Germany to develop next-generation…
Bayer reports steady 2020 performance despite Covid-19 pandemic
German-headquartered pharma company Bayer has published its 2020 annual report. The report suggests that Bayer had a robust 2020 despite the Covid-19 pandemic and there was positive momentum for solid…
Targeting immune diseases: Longwood Fund founds ImmuneID with $17m financing
Precision immunology company ImmuneID has launched with $17m in funding. The financing round was led by founding investor Longwood Fund; other investors participating in the round include XFund and Arch…
Precision medicine in AMD: SPAC merger sees Gemini make its public debut
Precision medicine-focused Gemini Therapeutics has completed a business combination transaction with Foresite Capital’s special purpose acquisition company (SPAC) FS Development Corp (FSDC). The deal was initiated in October 2021 and…
Humacyte agrees SPAC merger to go public with bioengineered tissue tech
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC). The deal allows Humacyte to become a…
Imcyse closes €21.3m Series B as new partner Pfizer takes equity stake
Belgium-based Imcyse has closed a €21.3m ($25.8m) Series B round. Investors participating in the round included Société Fédérale de Participations et d'Investissement (SFPI), Biogenosis and Katholieke Universiteit Leuven (KUL), the…
